Education
About Us
Working with TipRanks
Follow Us
Incyte (DE:ICY)
:ICY
ICY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€49.00 - €78.52
Previous CloseN/A
Volume0.00
Average Volume (3M)36.00
Market Cap
€10.57B
Enterprise Value€9.51B
Total Cash (Recent Filing)€2.41B
Total Debt (Recent Filing)$43.12M
Price to Earnings (P/E)171.4
Beta0.11
Next Earnings
Aug 05, 2025EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.04
Shares Outstanding193,569,930
10 Day Avg. Volume102
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio21.48
Price to Book (P/B)3.11
Price to Sales (P/S)0.00
P/FCF Ratio39.52
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue0.57
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda8.15
Forecast
1Y Price Target
€65.93Price Target Upside21.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyNew 18 week pivotal Phase 3 data for povorcitinib in hidradenitis suppurativa demonstrates continued improvement in the primary endpoint from week 12 in both parallel trials.
Financial OutlookAnalyst's price target increased to $95, reflecting the positive financial updates and pipeline advancements.
Sales GrowthJakafi sales exceeded expectations with a 10% growth over consensus estimates, driven by significant growth in polycythemia vera patients.
Bears Say
Competition And ExclusivityOpzelura revenue will be challenged by lower tube usage and assets like povorcitinib and axatilimab will not address the Jakafi loss of exclusivity.
Market PerformanceUnderperformance of Opzelura gives pause despite topline growth ahead of expectations.
Revenue ChallengesUnderperform rating supported by analysis suggesting Opzelura revenue will be challenged by lower tube usage.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.71% Insiders
21.96%
Mutual Funds
0.53% Other Institutional Investors
37.78% Public Companies and
Individual Investors
ICY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was €49.00 and its highest was €78.52 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is €10.57B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Aug 05, 2025 which is in 80 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Apr 29, 2025. The company reported €1.036 earnings per share for the quarter, beating the consensus estimate of €0.873 by €0.162.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.25.
How many shares outstanding does Incyte have?
Incyte has 193,569,930 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of €1.036 in its last earnings report, beating expectations of €0.873. Following the earnings report the stock price went up 3.206%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in DE:ICY
---
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€65.93 (21.83% Upside)
€65.93 (21.83% Upside)
Blogger Sentiment
Bullish
DE:ICY Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.00%
12-Months-Change
Fundamentals
Return on Equity
0.47%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
---
ICY Company Deck
---
ICY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue growth, successful product launches, and positive R&D progress. While there are potential challenges related to inventory management and competitive pressures, the overall sentiment remains optimistic due to the company's robust cash position and strategic planning.Read More>---
ICY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
---
ICY Stock 12 Month Forecast
Average Price Target
€65.93
▲(21.83% Upside)
Technical Analysis
---